Viking Therapeutics reported Phase 2 data for VK2735, an oral obesity drug demonstrating up to 12.2% weight loss after 13 weeks at the highest dose. While efficacy met statistical benchmarks, high discontinuation rates due to gastrointestinal side effects—38% in the highest dose group—disappointed investors. The adverse event profile and dropout rate dampened enthusiasm, sending the stock down 37% in premarket trading. Despite promising weight reduction results, questions remain concerning tolerability and long-term use, casting uncertainty on the drug’s commercial prospects.